ErVimmune, a preclinical biotechnology company focused on the development of cell therapies and cancer vaccines, has ...

Astellas Pharma has announced that the Scottish Medicines Consortium has accepted zolbetuximab for use on the NHS in Scotland ...

ARTCLINE, a biomedical company specialising in the development of immune cell treatments for septic shock, has announced the ...

More than 71% of patients treated with Unloxcyt achieved disease control ...

Tickets are on sale for the 40th anniversary of the PM Awards! Book now and join us on Friday 20 March 2026 at the JW Marriott Grosvenor House. This year, as a thank you for being a PM Society member, ...

Oxford Drug Design has announced new in vivo results that further validate its emerging first‑in‑class oncology programme, ...

AAX Biotech, a biotechnology company specialising in antibody therapeutics, and Vascurie, a biopharmaceutical company ...

Venner Shipley, an intellectual property (IP) law firm with focuses including life sciences, pharmaceuticals and medtech, has ...

Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

Ipsen has announced the presentation of new study data on Dysport (abobotulinumtoxinA) in stroke and other neurological ...

Cellistic has unveiled three new GMP manufacturing platforms designed to advance iPSC-derived cell therapies across ...

PMGroup Worldwide Ltd are pleased to announce their acquisition of the MAD World Summit and conference. This strategic ...